GT Biopharma, Inc. (GTBP)
0.2997
-0.01
(-1.99%)
USD |
NASDAQ |
Aug 25, 16:00
0.299
0.00 (0.00%)
After-Hours: 19:59
GT Biopharma Enterprise Value : 8.334M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 8.334M |
| August 24, 2026 | 8.607M |
| August 21, 2026 | 7.838M |
| August 20, 2026 | 7.544M |
| August 19, 2026 | 7.762M |
| August 18, 2026 | 7.249M |
| August 17, 2026 | 7.678M |
| August 14, 2026 | 8.169M |
| August 13, 2026 | 8.232M |
| August 12, 2026 | 8.442M |
| August 11, 2026 | 8.920M |
| August 10, 2026 | 9.268M |
| August 07, 2026 | 9.246M |
| August 06, 2026 | 8.392M |
| August 05, 2026 | 9.129M |
| August 04, 2026 | 9.514M |
| August 03, 2026 | 8.732M |
| July 31, 2026 | 8.057M |
| July 30, 2026 | 8.696M |
| July 29, 2026 | 8.428M |
| July 28, 2026 | 9.094M |
| July 27, 2026 | 9.871M |
| July 24, 2026 | 9.433M |
| July 23, 2026 | 9.92M |
| July 22, 2026 | 10.38M |
| Date | Value |
|---|---|
| July 21, 2026 | 10.95M |
| July 20, 2026 | 10.18M |
| July 17, 2026 | 10.84M |
| July 16, 2026 | 12.08M |
| July 15, 2026 | 10.60M |
| July 14, 2026 | 11.43M |
| July 13, 2026 | 12.27M |
| July 10, 2026 | 13.93M |
| July 09, 2026 | 14.92M |
| July 08, 2026 | 15.83M |
| July 07, 2026 | 15.49M |
| July 06, 2026 | 16.83M |
| July 02, 2026 | 16.02M |
| July 01, 2026 | 17.01M |
| June 30, 2026 | 16.82M |
| June 29, 2026 | 6.464M |
| June 26, 2026 | 6.112M |
| June 25, 2026 | 5.623M |
| June 24, 2026 | 7.030M |
| June 23, 2026 | 8.357M |
| June 22, 2026 | 8.241M |
| June 18, 2026 | 9.068M |
| June 17, 2026 | 7.132M |
| June 16, 2026 | 6.665M |
| June 15, 2026 | 7.474M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.379B |
| Alnylam Pharmaceuticals, Inc. | 31.79B |
| Anika Therapeutics, Inc. | 273.23M |
| Savara, Inc. | 1.008B |
| Vericel Corp. | 2.144B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.518M |
| Total Expenses (Quarterly) | 4.518M |
| EPS Diluted (Quarterly) | -0.1183 |
| Earnings Yield | -1.20K% |
| Normalized Earnings Yield | -2299.47 |